ABVC BioPharma, Inc. (OTCMKTS:ABVC – Get Rating) – Zacks Small Cap issued their Q1 2023 earnings estimates for ABVC BioPharma in a research report issued on Wednesday, January 18th. Zacks Small Cap analyst M. Marin anticipates that the company will post earnings of ($0.05) per share for the quarter. The consensus estimate for ABVC BioPharma's current full-year earnings is ($0.56) per share. Zacks Small Cap also issued estimates for ABVC BioPharma's Q2 2023 earnings at ($0.06) EPS, Q3 2023 earnings at ($0.05) EPS and Q4 2023 earnings at ($0.04) EPS.
Get ABVC BioPharma alerts:Separately, Maxim Group cut shares of ABVC BioPharma from a "buy" rating to a "hold" rating in a report on Wednesday, November 16th.
ABVC BioPharma Price Performance
ABVC opened at $0.78 on Thursday. The stock has a market capitalization of $25.46 million, a PE ratio of -1.15 and a beta of 0.50. The firm's fifty day moving average price is $0.75 and its 200 day moving average price is $0.80. ABVC BioPharma has a 12-month low of $0.50 and a 12-month high of $3.17.ABVC BioPharma (OTCMKTS:ABVC – Get Rating) last posted its quarterly earnings results on Monday, November 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.09. The company had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.03 million.
ABVC BioPharma Company Profile
(Get Rating)
ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage.
Further Reading
- Get a free copy of the StockNews.com research report on ABVC BioPharma (ABVC)
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
Receive News & Ratings for ABVC BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABVC BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.